Inventors:
Martha E. Rodriguez - Boulder CO, US
David A. Mareska - Boulder CO, US
Jeremy J. Hans - Saint Louis MO, US
Darren M. Harvey - Boulder CO, US
Robert D. Groneberg - Boulder CO, US
Michael O'Sullivan - Denver CO, US
Assignee:
ARRAY BIOPHARMA INC. - Boulder CO
International Classification:
A61K 31/454, C07D 417/14, C07D 413/14, C07D 409/06, C07D 417/06, C07D 401/06, A61K 31/4535, C07D 409/14, A61K 31/4725, C07D 471/04, A61K 31/437, C07D 498/04, A61K 31/5025, A61K 31/506, A61K 31/496, A61K 31/5377, A61P 3/10, C07D 413/06
US Classification:
5142102, 546209, 514326, 546201, 514323, 514318, 546194, 546213, 546211, 546141, 514309, 546113, 514300, 544236, 514248, 544324, 514275, 544364, 5142531, 544130, 5142368
Abstract:
A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I):wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1):wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.